Health Condition 1: F20- Schizophrenia
Conditions
Interventions
Intervention1: Lurasidone: 40mg-160mg, once daily dosage and oral intake for 6 weeks.
Control Intervention1: Olanzapine: 5mg-20mg, once daily dosage, oral intake for 6 weeks.
Sponsors
Alok Gupta
Eligibility
Inclusion criteria
Inclusion criteria: Patients giving informed consent, diagnosed with Schizophrenia as per ICD 10 diagnostic criteria and drug free for atleast 8 weeks.
Exclusion criteria
Exclusion criteria: Known case of diabetes mellitus, dyslipidemia and cardiac illness. Systemic or neurological Disorder affecting cognition, behavior or mental status. Substance dependence except nicotine and caffeine within the past month of entering the study.Long standing medical or surgical illness and patients with mental retardation or organic brain disease.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Positive and Negative Syndrome Scale, Brief Psychiatric Rating Scale, Clinical Global Impressions Scale â?? Impressions and Montreal Cognitive Assessment would be used to assess change in symptoms of Schizophrenia.Timepoint: At the time of enrollment in the study and at the end of 6 weeks. | — |
Secondary
| Measure | Time frame |
|---|---|
| Lipid Profile, Fasting Blood Sugar, Post Postprandial Blood Sugar and ECG would be done to assess change in cardio metabolic parameters in the patients.Timepoint: At the time of enrollment in the study and at the end of 6 weeks. | — |
Countries
India
Contacts
Public ContactAlok Gupta
IMS SUM Hospital
Outcome results
None listed